Clinical Trial News and Research

RSS

Northwestern Medicine receives $12 million to continue organ transplant research with stem cells

An innovative Northwestern Medicine- research program investigating if stem cells may be the key to allowing organ transplant patients to stop taking immunosuppressive drugs has received $12 million in research funding. The grant will allow researchers to finish Phase II of the clinical trials and begin Phase III.

8 Nov 2013

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

BioCryst Pharmaceuticals, Inc. today announced that it has dosed the first subject in OPuS-1 (Oral ProphylaxiS-1), a Phase 2a proof of concept clinical trial of orally-administered BCX4161 in patients with hereditary angioedema.

8 Nov 2013

Clinical testing expanded for vaccine against latent TB

Statens Serum Institut and Aeras today announced the initiation of a Phase I/IIa clinical trial for a candidate tuberculosis vaccine designed to protect people, especially those latently infected with TB, from developing active TB disease.

8 Nov 2013

Landmark clinical trial of artificial aortic heart valve shows positive results

Loyola University Medical Center is the only Chicago hospital participating in a landmark clinical trial of an artificial aortic heart valve that does not require open heart surgery.

From Medtronic 8 Nov 2013

$Risedronate may help prevent new vertebral fractures when taken with calcium and vitamin D$

Risedronate may help prevent new vertebral fractures when taken with calcium and vitamin D

A recent prospective, randomized, placebo-controlled clinical trial reports that calcium and vitamin D supplementation improves bone density in a group of male veterans with epilepsy who were treated chronically with antiepileptic drugs.

8 Nov 2013

Vitamin D and calcium improves bone density in male veterans treated with AEDs

8 Nov 2013

Diets and the famine reaction: an interview with Associate Professor Amanda Salis, University of Sydney

The statistic that you often hear is that 95% of diets fail, but in actual fact, emerging research is now showing that it’s around 70% of diets that fail. That means that around 30% of people who are losing weight are actually keeping it off. So we’re doing better now than we were doing in the past, but there’s still work to be done.

7 Nov 2013

ImmunGene secures $9 million in Series A financing from Ally Bridge Group

ImmunGene, Inc., a biotechnology company focused on developing antibody-cytokine fusion technology therapies to treat cancer, today announced it has secured $9 million in a milestone-based Series A financing from Ally Bridge Group. Previous investments in the Company were converted into Series A preferred stock. ImmunGene will use the capital to advance its early-stage development products to IND-enabling studies.

7 Nov 2013

Patrys receives FDA Orphan Medicinal Product Designation for PAT-SM6

Patrys Limited, a clinical stage biotechnology company, has received confirmation of Orphan Medicinal Product Designation for its lead anti-cancer product PAT-SM6, from the USA Food and Drugs Administration.

7 Nov 2013

Use of testosterone therapy after angiography associated with increased risk of death

Among a group of men who underwent coronary angiography and had a low serum testosterone level, the use of testosterone therapy was associated with increased risk of death, heart attack, or ischemic stroke, according to a study in the November 6 issue of JAMA.

6 Nov 2013

New drug combination therapy effectively kills cancer cells

Results from a recent preclinical study have shown that a new drug combination therapy being developed at Virginia Commonwealth University Massey Cancer Center effectively killed colon, liver, lung, kidney, breast and brain cancer cells while having little effect on noncancerous cells. The results lay the foundation for researchers to plan a future phase 1 clinical trial to test the safety of the therapy in a small group of patients.

6 Nov 2013

New treatment option for patients with most difficult-to-treat forms of hepatitis C

A novel single-pill combination drug could present a new treatment option for patients with the most difficult-to-treat forms of hepatitis C, according to the results of a Phase 2 trial, published in The Lancet.

6 Nov 2013

Furiex reports financial and operating results for third quarter 2013

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended September 30, 2013.

6 Nov 2013

Depomed reports financial results for third quarter 2013

Total revenues were $37.5 million and included recognition of a $5.0 million milestone payment from Mallinckrodt related to the NDA filing of MNK-795. Excluding this milestone and a $10 million upfront payment from Janssen in the third quarter of 2012, total revenues of $32.5 million grew 39% compared to $23.3 million for the third quarter of 2012.

6 Nov 2013

Sound Pharmaceuticals completes enrollment for SPI-1005 Phase 2 clinical trial

Sound Pharmaceuticals has successfully completed enrollment of its Phase 2 clinical trial with SPI-1005 at the University of Florida. This study enrolled 80 healthy subjects with normal or slight hearing loss and exposed the volunteer to calibrated music using an iPod and insert earphones.

5 Nov 2013

Cellular Biomedicine Group gets approval to conduct ReJoin Phase IIb trial for Knee Osteoarthritis

Cellular Biomedicine Group, Inc., a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that it has received approval to conduct a Phase IIb clinical trial for ReJoin, a human adipose-derived mesenchymal precursor cells (haMPC) therapy bio-engineered for Knee Osteoarthritis.

5 Nov 2013

Weight loss surgery: The most effective weapon for obese people in the battle against diabetes

Noted bariatric surgeon Michael Feiz, M.D., F.A.C.S., believes that there's no time like American Diabetes Month to point out that weight loss surgery is the most effective weapon obese people have in the battle against diabetes.

5 Nov 2013

Trophos completes efficacy study of olesoxime in patients with Spinal Muscular Atrophy

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, has completed its efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy.

5 Nov 2013

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Reviva Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the discovery and development of new, safer and highly effective therapies for chronic indications, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration for its lead, new investigational antipsychotic drug, RP5063.

5 Nov 2013

Pivotal Phase III STARTVerso data shows efficacy of faldaprevir in genotype-1 infected HCV patients

Boehringer Ingelheim today announced new data from its Phase III clinical trial programme, STARTVerso, which evaluates faldaprevir in combination with pegylated interferon and ribavirin (PegIFN/RBV).

5 Nov 2013

Clinical Trial News and Research

Northwestern Medicine receives $12 million to continue organ transplant research with stem cells

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

Clinical testing expanded for vaccine against latent TB

Landmark clinical trial of artificial aortic heart valve shows positive results

Risedronate may help prevent new vertebral fractures when taken with calcium and vitamin D

Vitamin D and calcium improves bone density in male veterans treated with AEDs

Diets and the famine reaction: an interview with Associate Professor Amanda Salis, University of Sydney

ImmunGene secures $9 million in Series A financing from Ally Bridge Group

Patrys receives FDA Orphan Medicinal Product Designation for PAT-SM6

Use of testosterone therapy after angiography associated with increased risk of death

New drug combination therapy effectively kills cancer cells

New treatment option for patients with most difficult-to-treat forms of hepatitis C

Furiex reports financial and operating results for third quarter 2013

Depomed reports financial results for third quarter 2013

Sound Pharmaceuticals completes enrollment for SPI-1005 Phase 2 clinical trial

Cellular Biomedicine Group gets approval to conduct ReJoin Phase IIb trial for Knee Osteoarthritis

Weight loss surgery: The most effective weapon for obese people in the battle against diabetes

Trophos completes efficacy study of olesoxime in patients with Spinal Muscular Atrophy

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Pivotal Phase III STARTVerso data shows efficacy of faldaprevir in genotype-1 infected HCV patients

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery